Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Diels van den Dobbelsteen"'
Autor:
Lilian Driessen-Engels, Roel J Arends, Désirée Damming, Wendela A Kappers, Gijs Verheijden, Mary J van Helden, Ronald C Elgersma, Daphne WJ van Kuppeveld, Dennis Waalboer, Ellen WH Santegoeds-Lenssen, Inge Leenders, Karin de Laat-Arts, Marc CBC Paradé, Menno Winkel, Anja Scholzen, Daniëlle EJW van Wijk, Diels van den Dobbelsteen, Genny Filiciotto, Laura Assink, Myrthe Rouwette, Panagiota I Spantidea, Timo K van den Berg, Wim HA Dokter, Miranda MC van der Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/0bdf2e0ad85f4e3c8e9e2cbae21d91f1
Autor:
Timo K van den Berg, Hugo Olsman, Hanke L Matlung, Katka Franke, Imke Lodewijks, Lilian Driessen-Engels, Mary J van Helden, Seline A Zwarthoff, Roel J Arends, Inge M J Reinieren-Beeren, Marc C B C Paradé, Karin de Laat-Arts, Désirée Damming, Ellen W H Santegoeds-Lenssen, Daphne W J van Kuppeveld, Ellen Mattaar-Hepp, Marloes E M Stokman, Benny de Wit, Dirk H R F Glaudemans, Daniëlle E J W van Wijk, Lonnie Joosten-Stoffels, Jan Schouten, Paul J Boersema, Monique van der Vleuten, Jorien W H Sanderink, Wendela A Kappers, Diels van den Dobbelsteen, Marco Timmers, Ruud Ubink, Gerard J A Rouwendal, Gijs Verheijden, Miranda M C van der Lee, Wim H A Dokter
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 4 (2023)
Background Preclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. Howev
Externí odkaz:
https://doaj.org/article/b070a5b304cf452fb3bfdad0492340e0
Autor:
Mary J van Helden, Seline A Zwarthoff, Roel J Arends, Inge M J Reinieren-Beeren, Marc C B C Paradé, Lilian Driessen-Engels, Karin de Laat-Arts, Désirée Damming, Ellen W H Santegoeds-Lenssen, Daphne W J van Kuppeveld, Imke Lodewijks, Hugo Olsman, Hanke L Matlung, Katka Franke, Ellen Mattaar-Hepp, Marloes E M Stokman, Benny de Wit, Dirk H R F Glaudemans, Daniëlle E J W van Wijk, Lonnie Joosten-Stoffels, Jan Schouten, Paul J Boersema, Monique van der Vleuten, Jorien W H Sanderink, Wendela A Kappers, Diels van den Dobbelsteen, Marco Timmers, Ruud Ubink, Gerard J A Rouwendal, Gijs Verheijden, Miranda M C van der Lee, Wim H A Dokter, Timo K van den Berg
Publikováno v:
van Helden, M J, Zwarthoff, S A, Arends, R J, Reinieren-Beeren, I M J, Paradé, M C B C, Driessen-Engels, L, de Laat-Arts, K, Damming, D S, Santegoeds-Lenssen, E W H, van Kuppeveld, D W J, Lodewijks, I, Olsman, H, Matlung, H L, Franke, K, Mattaar-Hepp, E, Stokman, M E M, de Wit, B, Glaudemans, D H R F, van Wijk, D E J W, Joosten-Stoffels, L, Schouten, J, Boersema, P J, van der Vleuten, M, Sanderink, J W H, Kappers, W A, van den Dobbelsteen, D, Timmers, M, Ubink, R, Rouwendal, G J A, Verheijden, G, van der Lee, M M C, Dokter, W H A & van den Berg, T K 2023, ' BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγon T cells ', Journal for Immunotherapy of Cancer, vol. 11, no. 4, jitc-2022-006567 . https://doi.org/10.1136/jitc-2022-006567
BackgroundPreclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. Howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f6e6308ed606888d418126a12792c8
https://research.vumc.nl/en/publications/67116c0e-064c-4154-86d3-6797beec296d
https://research.vumc.nl/en/publications/67116c0e-064c-4154-86d3-6797beec296d
Autor:
Marco Timmers, Gijs Verheijden, Guy de Roo, Michel Eppink, Vincent de Groot, Tijl Huijbregts, Henri Spijker, John Joosten, Wiro Menge, Ronald Elgersma, Ruud Coumans, Patrick Beusker, Patrick Groothuis, Ellen Mattaar, David Egging, Diels van den Dobbelsteen, Eline Loosveld, Danielle Jacobs, Tanja van Achterberg, Monique van der Vleuten, Miranda van der Lee, Ruud Ubink, Wim Dokter
Supplementary tables describe a comparison of half-lives of SYD983 in the different species (Table S1), PK details in mice (Table S2), PK details in tumor-bearing mice (Table S3), PK details in cynomolgus monkeys (Tables S4 and S5), Flow rates of SYD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::577fecc3721cf52f00190b2f91911f37
https://doi.org/10.1158/1535-7163.22502829.v1
https://doi.org/10.1158/1535-7163.22502829.v1
Autor:
Wim H.A. Dokter, Marco Timmers, Jacques M. Lemmens, Gijs F.M. Verheijden, Peter Goedings, Patrick H. Beusker, Diels van den Dobbelsteen, David F. Egging, Myrthe Rouwette, Daniëlle C.H. Jacobs, Désirée Damming, Eline M. Loosveld, Tanja A. van Achterberg, Monique A.J. van der Vleuten, Ruud Ubink, Patrick G. Groothuis, Miranda M.C. van der Lee
Table S1. Summary of status of tumors used in cell line and patient-derived xenograft models. Table S2. SYD985 and T-DM1 IC50, 95% confidence interval and % efficacy values from the in vitro cytotoxicity assays as depicted in Figure 1B. Table S3. Pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3603b07bdb54b39a88efa101b6977359
https://doi.org/10.1158/1535-7163.22501852
https://doi.org/10.1158/1535-7163.22501852
Autor:
Marco Timmers, Gijs Verheijden, Guy de Roo, Michel Eppink, Vincent de Groot, Tijl Huijbregts, Henri Spijker, John Joosten, Wiro Menge, Ronald Elgersma, Ruud Coumans, Patrick Beusker, Patrick Groothuis, Ellen Mattaar, David Egging, Diels van den Dobbelsteen, Eline Loosveld, Danielle Jacobs, Tanja van Achterberg, Monique van der Vleuten, Miranda van der Lee, Ruud Ubink, Wim Dokter
Details are given of the synthesis of SYD983 and the non-binding control, preparation of fluorescently-labeled SYD983, bioanalysis of SYD983 using SEC, HIC, and RP-HPLC, functional assays like an ADCC assay and internalization, and details on the PK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d71b8b769e05a9d69d5154dd46d72d7
https://doi.org/10.1158/1535-7163.22502832.v1
https://doi.org/10.1158/1535-7163.22502832.v1
Autor:
Mary van Helden, Seline Zwarthoff, Roel Arends, Inge Reinieren-Beeren, Marc Parade, Lilian Driessen-Engels, Karin de Laat-Arts, Desiree Damming, Ellen Santegoeds-Lenssen, Daphne van Kuppeveld, Imke Lodewijks, Ellen Mattaar, Hugo Olsman, Hanke Matlung, Katka Franke, Marloes Stokman, Benny de Wit, Dirk Glaudemans, Danielle van Wijk, Lonnie Joosten Stoffels, Jan Schouten, Paul Boersema, Monique van der Vleuten, Jorien Sanderink, Wendy Kappers, Diels van den Dobbelsteen, Marco Timmers, Ruud Ubink, Gerard Rouwendal, Gijs Verheijden, Miranda M.C. van der Lee, Wim Dokter, Timo van den Berg
Publikováno v:
Cancer Research. 83:2934-2934
A growing body of data from early clinical studies supports that targeting the myeloid immune checkpoint CD47-SIRPα represents a successful strategy towards establishing effective new therapies for cancer patients. Initial studies focused on CD47 bl
Autor:
Mary van Helden, Seline Zwarthoff, Hugo Olsman, Marc Paradé, Ellen Mattaar, Karin de Laat, Imke Lodewijks, Paul Boersema, Lilian Driessen-Engels, Jorien Sanderink, Wendy Kappers, Diels van den Dobbelsteen, Ruud Ubink, Roel Arends, Gerard Rouwendal, Gijs Verheijden, Miranda van der Lee, Wim Dokter, Timo Van den Berg
Publikováno v:
Cancer Research. 82:5589-5589
Preclinical data have established CD47-SIRPα interactions as a myeloid immune checkpoint in cancer, which is corroborated by preliminary evidence from the first clinical studies with CD47 blockers. However, the ubiquitously expressed CD47 mediates f
Autor:
Kim Berentsen, Patrick G. Groothuis, Marion Blomenrohr, Ronald Christiaan Elgersma, Wim H. A. Dokter, Danielle Jacobs, Miranda van der Lee, Monique van der Vleuten, Ruud Coumans, Patrick Henry Beusker, Diels van den Dobbelsteen, Ruud Ubink
Publikováno v:
Cancer Research. 81:925-925
5T4 is an oncofetal antigen with low expression in healthy tissues which is frequently overexpressed in different tumor types. Despite its overexpression in various malignancies and its association with poor prognosis, there are currently no marketed
Autor:
Patrick G. Groothuis, Myrthe Rouwette, Danielle Jacobs, Tanja van Achterberg, Desiree Damming, Wim H. A. Dokter, Jacques M. Lemmens, Miranda M.C. van der Lee, Diels van den Dobbelsteen, Eline Loosveld, Monique van der Vleuten, Peter Goedings, Patrick Henry Beusker, GF Verheijden, Marco Timmers, Ruud Ubink, David F. Egging
Publikováno v:
Molecular Cancer Therapeutics. 14:692-703
SYD985 is a HER2-targeting antibody–drug conjugate (ADC) based on trastuzumab and vc-seco-DUBA, a cleavable linker-duocarmycin payload. To evaluate the therapeutic potential of this new ADC, mechanistic in vitro studies and in vivo patient-derived